Prof Neeraj Agarwal talks to ecancer about the results of expanded cohort 6 of the COSMIC-021 study. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer.

He begins by talking about the background to the study, stating that cabozantinib may enhance response to immune checkpoint inhibitors by promoting an immune-permissive microenvironment.

Dr Agarwal then talks about the methodology explaining that eligible patients had measurable disease, radiographic progression in soft tissue after enzalutamide and/or abiraterone, and ECOG PS of 0 or 1. Prior chemotherapy for metastatic castration-sensitive prostate cancer was permitted.

He concludes by talking about the results, saying that cabozantinib + atezolizumab demonstrated clinically meaningful activity with a manageable safety profile in mCRPC, supporting a phase 3 study of cabozantinib + atezolizumab (CONTACT-02).

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.